‘The microbiome’ is everywhere in the press – and fast-increasing resources are devoted to it in labs worldwide. Biotechs are busy getting microbiome-modifying compounds of all kinds to the clinic while academics generate eye-watering amounts of genomic and metabolomic data. But when will drugs and other products (advanced nutrition, etc.) come out of all those efforts? The number of key phase Ib and phase II read-outs will reach an inflexion point in 2020 – will Pharma and the investor community adopt those projects more widely? And in the transition from lab to clinic to drug-on-market, can this new frontier learn from those who have gone before – a supply chain that scales, clear regulation and accessible options for patients?